New Group CEO is someone who understands Biocon's business synergy well: Kiran Mazumdar-Shaw

economictimes.indiatimes.com:

In an interview to ET Now, Kiran Mazumdar-Shaw, chairperson, Biocon, talks about the likely KRAs of new Group CEO Peter Bains. Excerpts below (edited for clarity):

ET Now: Can You give us an idea of the KRAs for Peter Bains? What is going to be the immediate priority, and what kind of value creation are you trying to achieve with this appointment?
Kiran Mazumdar-Shaw: Every one of our individual businesses is at an inflection point of high growth. We believe that this is an opportunity for us to create premium growth at a group level. That is what I think this strategy is all about.

Enhance Your Healthcare Expertise with High-Impact Courses

While our individual businesses are being valued, what is not being valued correctly, we believe, is the group value that is brought together by these three businesses.

Biocon is a very unique business entity in the sense that it brings very important complementary businesses under one roof. And it provides every stakeholder a huge value-creation opportunity in terms of investment. We believe that as a business, it is also a huge value creating opportunity for us.
Peter, who is a veteran when it comes to the pharma and biopharma industry in terms of his global experience, also understands the Biocon Group because he has basically played a very key role in Syngene. Through Syngene, he has understood the entire Biocon business very well because many of the capabilities and competencies that Biocon had were leveraged by Syngene during his time. He knows what this group synergy is all about.

Coming to his mandate, I think Peter is very clear